Addex Therapeutics (GB:0QNV) has released an update.
Addex Therapeutics reported a provisional net loss of CHF 1.5 million for the third quarter of 2024, affected by the prior quarter’s one-time gain from a partial business sale, while maintaining a nine-month net profit of CHF 8.3 million. The company’s cash position stands at CHF 3.3 million as of the end of September. Investors are closely watching the upcoming final results and business update scheduled for November 22, 2024.
For further insights into GB:0QNV stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Shareholder Alert for Flux Power Holdings, Inc. (NASDAQ:FLUX)
- ValueAct’s $1B Stake in Meta Platforms is a Constructive Bet, Not an Activist Move
- Spirit Airlines Plunges 63% on Possibility of Bankruptcy Deal Wiping Out Shareholders’ Wealth
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
